Immunization with DNA plasmids coding for crimean-congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice

Journal of Virology

Volumn 91, Issue 10, 2017, Pages

  Hinkula, Jorma ^a,b   Devignot, Stéphanie ^c,d   Åkerström, Sara ^f   Karlberg, Helen ^e   Wattrang, Eva ^f   Bereczky, Sándor ^e   Mousavi Jazi, Mehrdad ^e   Risinger, Christian ^g   Lindegren, Gunnel ^e   Vernersson, Caroline ^f   Paweska, Janusz ^h   van Vuren, Petrus Jansen ^h   Blixt, Ola ^g   Brun, Alejandro ⁱ   Weber, Friedemann ^c,d   Mirazimi, Ali ^e,f,j  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^f NATIONAL VETERINARY INSTITUTE   (Sweden)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

ⁱ Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Crimean Congo hemorrhagic fever virus; DNA vaccines; Neutralizing antibodies; Th1 Th2 responses; VLP

Indexed keywords

ALPHA INTERFERON RECEPTOR; ENVELOPE PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 12P70; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR; UBIQUITIN; ALPHA INTERFERON; CAPSID PROTEIN; DNA VACCINE; EPITOPE; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; SURVIVAL; TH1 CELL; TH2 CELL; VIRUS CAPSID; VIRUS LIKE AGENT; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; CHEMISTRY; DEFICIENCY; DISEASE MODEL; GENETICS; HEMORRHAGIC FEVER, CRIMEAN; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; NAIROVIRUS; VACCINE IMMUNOGENICITY; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOGENICITY, VACCINE; INTERFERON-ALPHA; MICE; MICE, KNOCKOUT; PLASMIDS; TH1 CELLS; TH2 CELLS; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS;

EID: 85018269924     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02076-16     Document Type: Article

References (35)

1. Barnwal B, Karlberg H, Mirazimi A, Tan YJ. 2016. The non-structural protein of Crimean-Congo hemorrhagic fever virus disrupts the mitochondrial membrane potential and induces apoptosis. J Biol Chem 291:582-592. https://doi.org/10.1074/jbc.M115.667436.
2. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. 2013. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 100: 159-189. https://doi.org/10.1016/j.antiviral.2013.07.006.
3. Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW. 2014. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. PLoS One 9:e91516. https://doi.org/10.1371/journal .pone.0091516.
4. Bente DA, Alimonti JB, Shieh WJ, Camus G, Stroher U, Zaki S, Jones SM. 2010. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 84: 11089-11100. https://doi.org/10.1128/JVI.01383-10.
5. Bereczky S, Lindegren G, Karlberg H, Akerstrom S, Klingstrom J, Mirazimi A. 2010. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol 91: 1473-1477. https://doi.org/10.1099/vir.0.019034-0.
6. Zivcec M, Safronetz D, Scott D, Robertson S, Ebihara H, Feldmann H. 2013. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon alpha/beta receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J Infect Dis 207: 1909-1921. https://doi.org/10.1093/infdis/jit061.
7. Mousavi-Jazi M, Karlberg H, Papa A, Christova I, Mirazimi A. 2012. Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine 30:6225-6229. https://doi.org/ 10.1016/j.vaccine.2012.08.003.
8. Papa A, Papadimitriou E, Christova I. 2011. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scand J Infect Dis 43: 225-229. https://doi.org/10.3109/00365548.2010.540036.
9. Papa A, Pappa S, Panayotova E, Papadopoulou E, Christova I. 2016. Molecular epidemiology of Crimean-Congo hemorrhagic fever in Bulgaria-an update. J Med Virol 88:769-773. https://doi.org/10.1002/jmv .24400.
10. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C. 2006. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24:4657-4666. https://doi.org/10.1016/ j.vaccine.2005.08.034.
11. Ghiasi SM, Salmanian AH, Chinikar S, Zakeri S. 2011. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin Vaccine Immunol 18:2031-2037. https://doi.org/10.1128/CVI.05352-11.
12. Liu J, Dai S, Wang M, Hu Z, Wang H, Deng F. 2016. Virus like particlebased vaccines against emerging infectious disease viruses. Virol Sin 31:279-287. https://doi.org/10.1007/s12250-016-3756-y.
13. Devignot S, Bergeron E, Nichol S, Mirazimi A, Weber F. 2015. A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus. J Virol 89:5957-5967. https://doi.org/10.1128/ JVI.03691-14.
14. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, Weber F, Bucht G. 2009. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus. Virology 385: 409-415. https://doi.org/10.1016/j.virol.2008.12.012.
15. Weber M, Gawanbacht A, Habjan M, Rang A, Borner C, Schmidt AM, Veitinger S, Jacob R, Devignot S, Kochs G, Garcia-Sastre A, Weber F. 2013. Incoming RNA virus nucleocapsids containing a 5=-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe 13: 336-346. https://doi.org/10.1016/j.chom.2013.01.012.
16. Boshra H, Lorenzo G, Rodriguez F, Brun A. 2011. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR+/+ mice upon lethal virus challenge. Vaccine 29:4469-4475. https://doi.org/10.1016/j.vaccine.2011.04.043.
17. Rodriguez F, Zhang J, Whitton JL. 1997. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 71: 8497-8503.
18. Ahmed AA, McFalls JM, Hoffmann C, Filone CM, Stewart SM, Paragas J, Khodjaev S, Shermukhamedova D, Schmaljohn CS, Doms RW, Bertolotti-Ciarlet A. 2005. Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus. J Gen Virol 86:3327-3336. https://doi.org/10.1099/vir .0.81175-0.
19. Rahpeyma M, Fotouhi F, Makvandi M, Ghadiri A, Samarbaf-Zadeh A. 2015. Crimean-Congo hemorrhagic fever virus Gn bioinformatic analysis and construction of a recombinant bacmid in order to express Gn by baculovirus expression system. Jundishapur J Microbiol 8:e25502. https://doi.org/10.5812/jjm.25502.
20. Bertolotti-Ciarlet A, Smith J, Strecker K, Paragas J, Altamura LA, McFalls JM, Frias-Staheli N, Garcia-Sastre A, Schmaljohn CS, Doms RW. 2005. Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins. J Virol 79:6152-6161. https://doi .org/10.1128/JVI.79.10.6152-6161.2005.
21. Kortekaas J, Vloet RP, McAuley AJ, Shen X, Bosch BJ, de Vries L, Moormann RJ, Bente DA. 2015. Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. Vector Borne Zoonotic Dis 15: 759-764. https://doi.org/10.1089/vbz.2015.1855.
22. Van Regenmortel MH. 2009. What is a B-cell epitope? Methods Mol Biol 524:3-20. https://doi.org/10.1007/978-1-59745-450-6_1.
23. Canakoglu N, Berber E, Tonbak S, Ertek M, Sozdutmaz I, Aktas M, Kalkan A, Ozdarendeli A. 2015. Immunization of knock-out alpha/beta interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Negl Trop Dis 9:e0003579. https://doi.org/10.1371/journal.pntd.0003579.
24. Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S. 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 151:1093-1099. https://doi.org/10.1093/infdis/151.6.1093.
25. Deyde VM, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST. 2006. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J Virol 80:8834-8842. https://doi.org/10.1128/JVI.00752-06.
26. Lorenzo G, Martin-Folgar R, Hevia E, Boshra H, Brun A. 2010. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR-/-mice induced by different DNA vaccination regimens. Vaccine 28:2937-2944. https://doi.org/10.1016/j.vaccine.2010.02.018.
27. Kaya A, Engin A, Guven AS, Icagasioglu FD, Cevit O, Elaldi N, Gulturk A. 2011. Crimean-Congo hemorrhagic fever disease due to tick bite with very long incubation periods. Int J Infect Dis 15:e449-452. https://doi .org/10.1016/j.ijid.2011.03.007.
28. Whitehouse CA. 2004. Crimean-Congo hemorrhagic fever. Antiviral Res 64:145-160. https://doi.org/10.1016/j.antiviral.2004.08.001.
29. Andersson I, Bladh L, Mousavi-Jazi M, Magnusson KE, Lundkvist A, Haller O, Mirazimi A. 2004. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J Virol 78:4323-4329. https:// doi.org/10.1128/JVI.78.8.4323-4329.2004.
30. Andersson I, Simon M, Lundkvist A, Nilsson M, Holmstrom A, Elgh F, Mirazimi A. 2004. Role of actin filaments in targeting of Crimean Congo hemorrhagic fever virus nucleocapsid protein to perinuclear regions of mammalian cells. J Med Virol 72:83-93. https://doi.org/10.1002/jmv.10560.
31. Bergeron E, Albarino CG, Khristova ML, Nichol ST. 2010. Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function. J Virol 84:216-226. https://doi.org/10.1128/JVI.01859-09.
32. Wolfel R, Paweska JT, Petersen N, Grobbelaar AA, Leman PA, Hewson R, Georges-Courbot MC, Papa A, Gunther S, Drosten C. 2007. Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients. Emerg Infect Dis 13:1097-1100. https://doi.org/10.3201/ eid1307.070068.
33. Clo E, Kracun SK, Nudelman AS, Jensen KJ, Liljeqvist JA, Olofsson S, Bergstrom T, Blixt O. 2012. Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. J Virol 86: 6268-6278. https://doi.org/10.1128/JVI.00392-12.
34. Olofsson S, Blixt O, Bergstrom T, Frank M, Wandall HH. 2016. Viral O-GalNAc peptide epitopes: a novel potential target in viral envelope glycoproteins. Rev Med Virol 26:34-548. https://doi.org/10.1002/rmv .1859.
35. Andersson I, Karlberg H, Mousavi-Jazi M, Martinez-Sobrido L, Weber F, Mirazimi A. 2008. Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J Med Virol 80:1397-1404. https://doi.org/10.1002/jmv.21222.